// App-Quantinova.ai

: Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Daniel Khalaf

Principal Investigators

  • Matti Annala

  • Kevin Beja

  • Gillian Vandekerkhove

  • Muhammad Zulfiqar

  • Daygen L. Finch

  • Conrad D. Oja

  • Joanna Vergidis

  • Martin Gleave

  • Alexander William Wyatt

  • Kim N. Chi

Medical Centers

  • BC Cancer Agency, Vancouver, BC, Canada

  • Institute of Biosciences and Medical Technology, Tampere, Finland

  • Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

  • Vancouver Prostate Centre, Vancouver, BC, Canada

  • BC Cancer Agency, Abbotsford, BC, Canada

  • British Columbia Cancer Agency, Southern Interior Centre, Kelowna, BC, Canada

  • British Columbia Cancer Agency, Abbotsford Centre, Vancouver, BC, Canada

  • BC Cancer Agency Vancouver Island Centre, Victoria, BC, Canada

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • British Columbia Cancer Agency, Vancouver, BC, Canada

Locations

  • Canada

  • Finland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating DNA

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved